WEDNESDAY, Aug. 14, 2024 -- For patients with advanced endometrial cancer (EC), sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2...

20 August 2024 -- GSK plc (LSE/NYSE: GSK) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation...

TUESDAY, Aug. 12, 2024 -- An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and...

The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory...

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in...

A pivotal study uncovers the molecular signatures of mammographic calcifications in hormone receptor-positive, HER2-negative breast cancer. The...

WEDNESDAY, Aug. 21, 2024 -- For women with early breast cancer, radiotherapy could prevent ipsilateral breast cancer recurrence for 10 years, but...

16 August 2024 -- AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult...

CRANBURY, N.J.–(BUSINESS WIRE) Aug 14, 2024 –Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence...

The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or...